Ipilimumab/nivolumabInsulin dependent diabetes mellitus: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1938卷 / 1期

关键词：

D O I：

10.1007/s40278-023-30900-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：759 / 759

相关论文

共 50 条

[31] Ipilimumab/nivolumabThyroiditis: 2 case reports
Reactions Weekly, 2023, 1939 (1) : 257 - 257
[32] Ipilimumab/nivolumabColitis: 2 case reports
Reactions Weekly, 2019, 1735 (1) : 160 - 160
[33] Ipilimumab/nivolumabSarcoidosis: 2 case reports
Reactions Weekly, 2019, 1744 (1) : 167 - 167
[34] Ipilimumab/nivolumabPneumonitis: 2 case reports
Reactions Weekly, 2020, 1787 (1) : 305 - 305
[35] Atezolizumab/Ipilimumab/NivolumabType 1 diabetes mellitus and isolated adrenocorticotropic hormone deficiency: 3 case reports
Reactions Weekly, 2024, 2021 (1) : 91 - 91
[36] Ipilimumab/pembrolizumabHypophysitis: 2 case reports
Reactions Weekly, 2018, 1714 (1) : 242 - 242
[37] Ipilimumab/nivolumabColitis: 2 case reports
Reactions Weekly, 2020, 1788 (1) : 135 - 135
[38] Ipilimumab/nivolumabHepatitis: 2 case reports
Reactions Weekly, 2017, 1665 (1) : 164 - 164
[39] NivolumabFulminant type 1 diabetes mellitus and type 1 diabetes mellitus: 2 case reports
Reactions Weekly, 2017, 1654 (1) : 254 - 254
[40] AsparaginaseAcute pancreatitis leading to insulin dependent diabetes mellitus: 4 case reports
Reactions Weekly, 2021, 1842 (1) : 63 - 63

← 1 2 3 4 5 →